EDAP TMS Reports Continued Progress in European Marketing

EDAP TMS Reports Continued Progress in European Marketing 


LYON, France, July 12  /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP) is
pleased to report continued growing interest in minimally invasive prostate
cancer treatment utilizing the company's market leading Ablatherm(R)-HIFU
platform at two conferences held in Europe.

EDAP participated in the 6th International Consultation on New Developments in
Prostate Cancer and Prostate Diseases, co-sponsored by the International Union
Against Cancer, in Paris, June 24-27, 2005. The conference is the most
recognized worldwide event for discussing prostate cancer and prostate disease
while assessing new trends in the fast developing area of research against
cancer.

Pr. Pierre Conort, from Hopital La Pitie Salpetriere in Paris, presented an
overview of features unique to Ablatherm(R)-HIFU including safety, quality
ultrasound imaging, long-term clinical data, reduced occurrence of side effects
and repeatability of treatment while discussing key factors differentiating
Ablatherm-HIFU from other technology. Pr. Conort has used Ablatherm-HIFU to
successfully treat localized prostate cancer for more than four years.

Pr. Pierre Conort commented: "Ablatherm-HIFU is the only proven technology
based on long-term clinical data. It has been used on a routine basis, for
well-selected patients whose treatment requires its unique benefits, since
2001. Ablatherm-HIFU treatment has a multi-year body of clinical data
demonstrating very low side effects and high tolerance in patients.
Additionally, it is a valuable option for patients who failed a prior
radiotherapy procedure and do not have other alternatives for their prostate
cancer treatment."

The Ablatherm-HIFU unit recently introduced an industry leading enhanced 3-D
integrated imaging system allowing the urologist to efficiently visualize the
patient prostate while focusing the high intensity ultrasound. Using the
optimized parameters developed based on years of clinical practice, urologists
can safely and effectively treat localized prostate cancer. The continuous
refinement of these parameters has steadily reduced the incidence of typical
side effects reported in other traditional treatments while offering the
patient an easier recovery as compared to surgical removal of the diseased
prostate.

Dr. John Warner, from the Don Mills Surgical Unit in Toronto, Canada, presented
a video session on Ablatherm-HIFU detailing an Ablatherm treatment procedure
and discussing the various steps. Dr. Warner also discussed how the newly
integrated imaging system enhances detail in imaging and control for the
physician during treatment. He concluded by presenting Ablatherm-HIFU five-year
results and successful outcomes for radiotherapy failure patients. This
presentation was highly attended and urologists demonstrated great interest in
inquiring further about this technique and its unique advantages.

EDAP also presented at the B.A.U.S. (British Association of Urology Surgeons)
meeting held in Glasgow, Scotland, from June 27 to July 1, 2005. Ablatherm-HIFU
received approval from the National Institute for Clinical Excellence (NICE) in
early 2005, a key recommendation for acceptance within the U.K. urology
community as well as future insurance reimbursement of the procedure. British
Urologists showed great interest specifically in Ablatherm-HIFU technology as
an additional treatment option for patients who are ill equipped to handle the
rigors of surgery or who failed previous radiation treatment. Urologists
visited with representatives from both EDAP and its U.K. distributor Sigmacon
to discuss Ablatherm-HIFU treatment of prostate cancer as well as take part in
informational discussions about the technology and its results.

"We are very pleased with the outcomes from these two conference events in
furthering the demand for and recognition of Ablatherm-HIFU as the leading
minimally invasive therapeutic option for the treatment of localized prostate
cancer in Europe," said Hugues de Bantel, CEO of EDAP. "EDAP will continue to
build on its strength in clinical results as we successfully treat an ever
increasing number of patients seeking an alternative to traditional therapies
for localized prostate cancer."

Commenting on the company's continued growth in the U.K. market, de Bantel
stated, "We are very pleased to begin active work in the U.K. to advance the
knowledge of this very attractive treatment option within the urology
community. The pipeline is building for the U.K. market as we continue in our
efforts to gain reimbursement approval."

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically
proven choice for High Intensity Focused Ultrasound (HIFU) treatment of
localized prostate cancer. HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side effects. The
company is also developing this technology for the treatment of certain other
types of tumors. EDAP TMS S.A. also produces and commercializes medical
equipment for treatment of urinary tract stones using Extra-corporeal Shockwave
Lithotripsy (ESWL).

For more information on the Company, contact the Investor Relations Dept by
phone at [phone] or see the Company's Web site at:
http://www.edap-tms.com/ .

This press release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties. These include
statements regarding the Company's growth and expansion plans. Such statements
are based on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ materially
from those described in the forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described in the
Company's filings with the Securities and Exchange Commission.

   CONTACT: EDAP TMS S.A.
   Hugues de Bantel - Philippe Chauveau
   Blandine Confort
   [phone]

   Halliburton Investor Relations
   Matt Kreps - Geralyn DeBusk
   972 458 8000


DATASOURCE: EDAP TMS S.A.



CONTACT:  Hugues de Bantel, Philippe Chauveau, or Blandine Confort, all

of EDAP TMS S.A., [phone]; or Matt Kreps, or Geralyn DeBusk, both of

Halliburton Investor Relations, [phone], for EDAP TMS S.A.



Web site:  http://www.edap-tms.com/ 

Copyright